高血压代谢组学研究进展

Research progress in metabolomics of hypertension

高血压与脑卒中、心衰等多种心脑血管疾病的发生发展密切相关。严格控制血压可降低相关疾病的发病率和病死率,但目前高血压的知晓率、诊断率、治疗率、达标率仍不理想。其中达标率低下的原因主要包括原发性高血压发病机制不明确、一线药物多样化、适用人群不明确等。近年来,代谢组学研究为高血压的发病机制、生物标记物筛选、药理作用及疗效安全性评估等方面提供了新的思路。文章主要针对高血压代谢组学的研究方法,及与高血压和抗高血压药物相关的代谢组学研究结果进行综述,为进一步深入开展相关研究提供借鉴。

Hypertension is closely related to the occurrence and development of cerebrovascular diseases,such as stroke and heart failure. Intensive blood pressure control can reduce the morbidity and mortality of related diseases. However,the awareness rate,diagnosis rate,treatment rate of hypertension and control rate of hypertension are still not satisfactory. The reasons of low control rate mainly include the unclear pathogenesis,the diversification of first-line drugs,and the varied response for different population. In recent years,metabolomics studies have provided new perspectives for the pathogenesis of hypertension,biomarker screening,pharmacological action of related drugs,efficacy and safety assessment of medication. In this paper,the research methods and the results of metabolomics research related to hypertension and antihypertensive drugs are reviewed,so as to provide reference for further research.